SCHEMBL22556464

SCHEMBL22556464

CN(C(=O)OC(C)(C)C)C(C)(C)CC(=O)NNC(=O)c1ccccc1Nc1ccc(C(F)(F)F)cc1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 12/20 0.43
▸ MAPK8 P45983 1/20 0.39
▸ ABCG2 Q9UNQ0 1/20 0.37
▸ TAS2R14 Q9NYV8 1/20 0.36
▸ AKR1C3 P42330 1/20 0.36
▸ AKR1C2 P52895 1/20 0.36
▸ SIRT2 Q8IXJ6 1/20 0.36
▸ MAPK9 P45984 1/20 0.36
▸ MAPK10 P53779 1/20 0.36
▸ YAP1 P46937 1/20 0.36
▸ TEAD4 Q15561 1/20 0.36
▸ TEAD2 Q15562 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ PPARD Q03181 1/20 0.36
▸ PPARA Q07869 1/20 0.36
▸ NR1H4 Q96RI1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22556510 0.87 RXFP1 (0.45) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL22556318 0.85 RXFP1 (0.45) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL22556345 0.85 RXFP1 (0.43) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL22556350 0.84 TRPV4 (0.43) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL22556555 0.83 RXFP1 (0.42) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL23713139 0.83 RXFP1 (0.48) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL22571429 0.83 RXFP1 (0.46) RXFP1MAPK8ABCG2TAS2R14
SCHEMBL30463789 0.83 RXFP1 (0.46) RXFP1MAPK8ABCG2TAS2R14
SCHEMBL22571359 0.82 PSMB5 (0.43) RXFP1MAPK8ABCG2TAS2R14AKR1C3
SCHEMBL30463790 0.82 PSMB5 (0.43) RXFP1MAPK8ABCG2TAS2R14AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
EP-3793551-A1 OXADIAZOLE COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-03-24 — — EP disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 — — WO disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 RXFP1 3511/4885MAPK8 986/4885ABCG2 2985/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 RXFP1 3511/4885MAPK8 986/4885ABCG2 2985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback